Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GENFIT
  6. Company
    GNFT   FR0004163111

GENFIT

(GNFT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo GENFIT
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Number of employees : 130 people.
Sales per Business
20192020Delta
Research and Development of Innovative Medicines and Diagnostic Solutions30.84100%0.77100% -97.52%
EUR in Million
Sales per region
20192020Delta
France30.84100%0.77100% -97.52%
EUR in Million
Managers
Name Title Age Since
Pascal Prigent CEO & EVP-Marketing & Development 52 2019
Thomas Baetz Chief Financial Officer 46 2021
Carol L. Addy, Dr. Chief Medical Officer 60 2019
Dean W. Hum, Dr. Chief Operating Officer 57 2018
Stefanie Magner Chief Compliance Officer - 2021
Nathalie Huitorel Chief Administrative Officer & Executive VP 58 2021
Xavier Guille des Buttes Vice Chairman 78 2017
Frédéric Joël Desdouits, Dr. Independent Director 53 2017
Anne-Hélène Monsellato Independent Director 53 2017
Catherine Larue, Dr. Independent Director 64 2017
Members of the board
Name Title Age Since
Jean-François Mouney Chairman 64 2019
Florence Séjourné Director 49 2017
Xavier Guille des Buttes Vice Chairman 78 2017
Frédéric Joël Desdouits, Dr. Independent Director 53 2017
Anne-Hélène Monsellato Independent Director 53 2017
Catherine Larue, Dr. Independent Director 64 2017
Katherine Bach Kalin Independent Director 57 2020
Eric Baclet Independent Director 60 2020
Jean-François Tiné Independent Director 63 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 45,775,250 43,230,332 94.4% 0 0.0% 94.4%
Shareholders
NameEquities%
Biotech Avenir SAS 1,888,618 4.12%
The Vanguard Group, Inc. 835,171 1.82%
Universite de Lille II Foundation 651,250 1.42%
BlackRock Fund Advisors 466,581 1.02%
Citadel Advisors LLC 462,177 1.01%
Syquant Capital SAS 182,751 0.40%
Société Générale Gestion SA 122,012 0.27%
Genfit SA 97,305 0.21%
Amundi Asset Management SA (Investment Management) 67,437 0.15%
BlackRock Advisors (UK) Ltd. 66,165 0.14%
Holdings
NameEquities%Valuation
GENFIT (GNFT) 97,305 0.21% 343,674 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- Bloomberg Code :  ALGFT:FP
- Reuters Code :  GNFT.PA
- Datastream Code :  
Company contact information
GENFIT
Parc Eurasanté 885 Avenue Eugène Avinée
FR-59120 Loos

Phone : +33 (0)3 20 16 40 00
Fax : +33 (0)3 20 16 40 01
web site : http://www.genfit.fr
Brand Portfolio
In partnership withAllbrands.markets
More brands of GENFIT
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
GENFIT-25.35%154
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548
PHARMARON BEIJING CO., LTD.57.96%22 426
ICON PUBLIC LIMITED COMPANY39.50%22 140
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.50.20%18 938
BIO-TECHNE CORPORATION49.10%18 605
HANGZHOU TIGERMED CONSULTING CO., LTD-12.75%18 314
PPD, INC.38.37%16 639
NOVAVAX, INC.95.47%16 480
INCYTE CORPORATION-21.38%15 105
QIAGEN N.V.6.85%12 820
PRA HEALTH SCIENCES, INC.0.00%10 965
BACHEM HOLDING AG72.19%10 880
GENSCRIPT BIOTECH CORPORATION255.50%10 799
SYNEOS HEALTH, INC.45.02%10 245
UNITED THERAPEUTICS CORPORATION27.57%8 721
Connections : GENFIT